Comparing a new cell therapy (zola-cel) to standard care for active systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of systemic sclerosis with specific antibodies (ANA nucleolar pattern or anti-Scl-70).
- You must have significant lung scarring (interstitial lung disease affecting at least 10% of your lung) plus active disease signs (like arthritis, muscle inflammation, heart inflammation, worsening skin, or high inflammation markers).
- You must have tried at least one immune-suppressing medication for 6 months without success or had bad side effects.
- You cannot need oxygen therapy or have very low lung function (DLCO ≤ 40%).
- You cannot have moderate to severe pulmonary hypertension requiring combination treatment.
- You cannot currently smoke or have used cigarettes or e-cigarettes in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.